LORMÉTAZÉPAM

D N05CD06(WHO) BR:Class B1(Psychoactive drugs)CA:Schedule IVDE: Prescription only (Anlage IIIfor higher doses)US:Schedule IV (RS)-7-Chloro-5-(2-chlorophenyl)-3-hydroxy-1-methyl-1H-benzo[e][1,4]diazepin-2(3H)-one 848-75-9N 13314 7553 DB13872Y 12750Y GU56C842ZA D01657Y CHEBI:52993Y ChEMBL22097Y DTXSID40862442 Interactive image ClC1=CC=CC=C1C2=NC(C(N(C)C3=C2C=C(C=C3)Cl)=O)O InChI=1S/C16H12Cl2N2O2/c1-20-13-7-6-9(17)8-11(13)14(19-15(21)16(20)22)10-4-2-3-5-12(10)18/h2-8,15,21H,1H3YKey:FJIKWRGCXUCUIG-UHFFFAOYSA-NY Lormetazepam, sold under the brand nameNoctamidamong others, is a drug which is a short to intermediate acting 3-hydroxybenzodiazepinederivative andtemazepamanalogue.It possesseshypnotic,anxiolytic,anticonvulsant,sedative, and skeletalmuscle relaxantproperties. It was patented in 1961 and came into medical use in 1980.Lormetazepam is not approved for sale in the United States or Canada. It is licensed in the UK as 0.5 and 1mg tablets for short-term treatment (2–4 weeks) of moderately severe insomnia. It is licensed in theNetherlandsas 1 and 2mg tablets, under the brand names Loramet and Noctamid and as generic, available from several manufacturers. It is sold in Poland as Noctofer. It is also sold inFranceas generic as 1 and 2mg tablets, with a maximum prescription duration of 4 weeks. ADutchanalysis stated that lormetazepam could be suitable to be included in drug prescribing formularies, althoughzolpidem,zopiclone, andtemazepamappear better.